New wrinkle treatment could be as easy as a shot

NCT ID NCT07321834

Ongoing Symptom relief Sponsor: Eirion Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 study tests AI-09, a ready-to-use liquid botulinum toxin, for treating moderate to severe frown lines between the eyebrows. About 68 adults aged 20 to 70 will receive either AI-09 or an inactive placebo injection. The goal is to see if AI-09 safely and effectively reduces the appearance of these lines.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AI-09 (ready-to-use liquid botulinum toxin)
What this could lead to: If it works, this could offer a more convenient, ready-to-use option for temporarily reducing frown lines.
What could go wrong: This is an early Phase 2 study with only 68 participants, so results may not confirm effectiveness or safety. As with any botulinum toxin, temporary bruising, headache, or eyelid drooping are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLABELLAR LINES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLABELLAR LINES

Contacts and locations

Locations

Center for Clinical and Cosmetic Research

Aventura, Florida, 33180, United States
Delricht Research

New Orleans, Louisiana, 70115, United States
Research Institute of the Southeast, Inc.

West Palm Beach, Florida, 33401, United States
Research Your Health

Plano, Texas, 75093, United States
Tennessee Clinical Research Center

Nashville, Tennessee, 37215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.